Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
OMX Ventures is a venture capital firm founded in 2020, headquartered in Lincolnshire, Illinois, with an additional presence in Boston. The firm was established to support the development of scalable biotech companies by employing a technology-first approach. OMX Ventures specializes in identifying transformative technologies within the biotech sector, particularly in therapeutics, bio-tools, diagnostics, and synthetic biology.
As of now, OMX Ventures manages a fund size of over $150 million, which was oversubscribed and announced in March 2021. The firm focuses on early-stage investments, specifically Seed and Series A funding, targeting innovations that address significant market needs. The team consists of experienced professionals who have worked together for several years prior to founding the firm, ensuring a cohesive approach to investment and company creation.
OMX Ventures aims to create impactful solutions that meet the demands of large markets, leveraging their expertise in biology, big data, and artificial intelligence. The firm is committed to fostering the growth of its portfolio companies through strategic guidance and industry connections.
OMX Ventures specializes in Seed and Series A funding, primarily targeting transformative technologies in the biotech sector. The firm invests across the United States, the United Kingdom, and Europe, focusing on innovations that address unmet needs in large markets. Key sectors of interest include therapeutics, bio-tools, diagnostics, and synthetic biology.
The firm employs a technology-first approach, emphasizing the convergence of biology, big data, and AI in its investment strategy. OMX Ventures seeks to identify companies that are not only innovative but also capable of scaling effectively in the competitive biotech landscape. The firm looks for founders who demonstrate a strong vision and the ability to execute their ideas, as well as technologies that have the potential to create significant market impact.
OMX Ventures has built a notable portfolio of companies that exemplify its focus on transformative biotech technologies. Key portfolio companies include:
These companies reflect OMX Ventures' commitment to investing in innovative solutions that address significant challenges in the biotech sector.
Dan Fero - Managing Director: Dan co-founded OMX Ventures and has extensive experience in the biotech sector, focusing on investment strategies and company creation.
Craig Asher - Managing Director: Craig brings a wealth of knowledge in venture capital and has been instrumental in identifying promising biotech innovations.
Nick Haft - Managing Director: Nick has a strong background in biotech investments and plays a key role in the firm's strategic direction.
Swetha Murali - Vice President: Swetha specializes in operational support for portfolio companies, leveraging her expertise in the biotech industry.
Natasha Azar - Vice President, Investor Relations: Natasha manages relationships with investors and stakeholders, ensuring effective communication and engagement.
Tim Richardson - Venture Partner: Tim provides strategic insights and guidance to portfolio companies, drawing from his extensive industry experience.
John Nawrocki - Chief Financial Officer: John oversees the financial operations of OMX Ventures, ensuring sound financial management and reporting.
Paul Conley - Venture Partner: Paul contributes to the firm's investment strategy and supports portfolio companies with his industry expertise.
Fred Sweeney - Venture Partner: Fred brings a wealth of experience in venture capital and provides valuable insights to the firm's investment decisions.
To pitch OMX Ventures, founders should use the contact email provided on their website: info@omx.vc. It is essential to include a comprehensive pitch deck that outlines the technology, market opportunity, and team qualifications. Founders should expect a response within a few weeks, although timelines may vary based on the volume of inquiries.
Warm introductions are preferred, as they can facilitate a more favorable review process. Founders are encouraged to highlight any existing traction or partnerships that demonstrate the viability of their business model.
In March 2021, OMX Ventures announced the successful closing of its first fund, which exceeded $150 million and was oversubscribed. This milestone marked a significant achievement for the firm, allowing it to expand its investment activities in the biotech sector.
OMX Ventures has been actively building its portfolio, with notable investments in companies such as Delix Therapeutics and Freya Biosciences, which focus on innovative solutions in mental health and women's health, respectively.
As of April 2023, OMX Ventures continues to seek out transformative biotech technologies, maintaining a strong presence in the investment community and participating in industry events to connect with potential founders and partners.
What are OMX Ventures' investment criteria?
OMX Ventures focuses on Seed and Series A investments in the biotech sector, specifically targeting transformative technologies that address unmet needs in large markets. The firm looks for innovations in therapeutics, bio-tools, diagnostics, and synthetic biology.
How can I pitch to OMX Ventures?
Founders can pitch OMX Ventures through their website at omx.vc. It is recommended to include a clear overview of the technology, market potential, and team background in the pitch deck.
What makes OMX Ventures different from other VCs?
OMX Ventures employs a technology-first approach, leveraging expertise in biology, big data, and AI to support portfolio companies. This approach allows them to provide strategic guidance and resources that are tailored to the unique challenges of the biotech industry.
What is the geographic scope of OMX Ventures?
The firm invests primarily in the United States, the United Kingdom, and Europe, focusing on early-stage biotech companies within these regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, OMX Ventures focuses on Seed and Series A funding rounds, which typically range from several hundred thousand to a few million dollars.
What kind of support do portfolio companies receive post-investment?
OMX Ventures provides strategic guidance, industry connections, and operational support to help portfolio companies scale and succeed in the competitive biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.